SKYE 250117 7.50C (SKYE250117C7500) Stock Options, News & Quotes

0.00
0.000.00%

15min DelayTrading Jan 21 09:30 ET

0.00High0.00Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Stock_Drift

Jan 12 18:12

$SKYE BIOSCIENCE INC (SKYE.US)$ $Sweetgreen (SG.US)$

Trytosaveabit

Nov 14, 2024 06:02

Update

$SKYE BIOSCIENCE INC (SKYE.US)$ Reuters· 1 min ago
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor

Jaguar8

Sep 23, 2024 06:03

NEWS

$SKYE BIOSCIENCE INC (SKYE.US)$
Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan
Skye Bioscience (Nasdaq: SKYE) has commented on Novo Nordisk's Phase 2a top-line data for monlunabant, a small-molecule oral CB1 inverse agonist. The study met its primary endpoint, showing at least 6% placebo-adjusted weight loss at 16 weeks. However, dose-dependent neuropsychiatric side effects were observed.
Skye highlights the advan...

Jaguar8

Aug 22, 2024 06:03

NEWS

$SKYE BIOSCIENCE INC (SKYE.US)$
Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity. Skye Bioscience (Nasdaq: SKYE) has launched a Phase 2 clinical trial, CBeyond™, to evaluate its peripheral CB1 inhibitor, nimacimab, for weight loss in patients with obesity.
The study will assess nimacimab's efficacy as a monotherapy and in combination with a GLP-1 receptor agonist (Wegovy®). Key aspects of the trial include:
- 12...

Skinny bulldog

May 20, 2024 07:43

$Scorpius Holdings (SCPX.US)$ Look at their peers. This is really undervalued. Once in a lifetime opporturnity.
$SKYE BIOSCIENCE INC (SKYE.US)$ $Boundless Bio (BOLD.US)$